Considering that Bevacizumab, an approved anti-angiogenic antibody, works by binding to VEGF and preventing it from interacting with endothelial cell surface receptors, thereby inhibiting tumor angiogenesis [34], and that lumbrokinase was found to inhibit the expression and secretion of VEGF, we hypothesized the synergy of lumbrokinase with bevacizumab in anti-tumorigenesis. Here, VEGFA is linked to neoplasm.